Advertisement
[adinserter block="11" template="Global Header" check="exceptions" ignore="page-type"]
Home »

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Jun 12, 2023

ABOUT THE EXPERTS

  • G Villacampa

    SOLTI Breast Cancer Research Group, Barcelona, Spain; Oncology Data Science, Vall d’Hebron Institute of Oncology, Barcelona, Spain.

    N M Tung

    Beth Israel, Boston, USA.

    S Pernas

    Medical Oncology Department, Catalan Institute of Oncology, 08908, L’Hospitalet de Llobregat, Barcelona, Spain.

    L Paré

    Reveal Genomics, Barcelona, Spain.

    C Bueno-Muiño

    Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, 28009 Madrid, Spain.

    I Echavarría

    Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid, Spain.

    S López-Tarruella

    Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007 Madrid, Spain.

    M Roche-Molina

    Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

    M Del Monte-Millán

    Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid, Spain.

    M Marín-Aguilera

    Reveal Genomics, Barcelona, Spain.

    F Brasó-Maristany

    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    A G Waks

    Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

    T Pascual

    SOLTI Breast Cancer Research Group, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    O Martínez-Sáez

    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    A Vivancos

    Cancer Genomics Group, VHIO, Barcelona, Spain.

    P F Conte

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Istituto Oncologico Veneto, IRCCS, Padova, Italy.

    V Guarneri

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Istituto Oncologico Veneto, IRCCS, Padova, Italy.

    M Vittoria Dieci

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Istituto Oncologico Veneto, IRCCS, Padova, Italy.

    G Griguolo

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Istituto Oncologico Veneto, IRCCS, Padova, Italy.

    J Cortés

    International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona, Spain.

    A Llombart-Cussac

    Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain.

    M Muñoz

    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    M Vidal

    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    B Adamo

    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.

    A C Wolff

    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.

    A DeMichele

    Department of Oncology, University of Pennsylvania, Philadelphia, USA.

    P Villagrasa

    Reveal Genomics, Barcelona, Spain.

    J S Parker

    Lineberger Comprehensive Cancer Center; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, USA.

    C M Perou

    Lineberger Comprehensive Cancer Center; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, USA.

    A Fernandez-Martinez

    Lineberger Comprehensive Cancer Center; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, USA.

    L A Carey

    Lineberger Comprehensive Cancer Center; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, USA.

    E A Mittendorf

    Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA.

    M Martín

    Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007 Madrid, Spain.

    A Prat

    Reveal Genomics, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: alprat@clinic.cat.

    S M Tolaney

    Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sara_tolaney@dfci.harvard.edu.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
[adinserter block="6" template="Third Party Article - PubMed" check="exceptions" ignore="page-type"]